In treatment of patients with surgical intervention-maladaptive progressing renal clear cell cancer, sunitinib (VEGF receptor-tyrosine kinase inhibitor (VEGFR-TKI)), bevacizumab (anti-VEGF antibody) plus interferon-α, pazopanib (VEGFR-TKI), temsirolimus, everolimus, axitinib (VEGFR-TKI), and sorafenib (VEGFR-TKI) are approved [47,48]. The gene discussed is KDR; the disease is clear cell renal carcinoma.